The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers
Keiji Hirai, Junki Morino, Saori Minato, Shohei Kaneko, Katsunori Yanai, Yuko Mutsuyoshi, Hiroki Ishii, Momoko Matsuyama, Taisuke Kitano, Mitsutoshi Shindo, Akinori Aomatsu, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara, Yoshiyuki Morishita Division of Nephrology, First Department...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2d0096a0788643f19bc4f1fe2dcd0bec |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:2d0096a0788643f19bc4f1fe2dcd0bec |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:2d0096a0788643f19bc4f1fe2dcd0bec2021-12-02T05:33:15ZThe Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers1178-7007https://doaj.org/article/2d0096a0788643f19bc4f1fe2dcd0bec2020-01-01T00:00:00Zhttps://www.dovepress.com/the-efficacy-and-safety-of-sodium-glucose-cotransporter-2-inhibitors-i-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Keiji Hirai, Junki Morino, Saori Minato, Shohei Kaneko, Katsunori Yanai, Yuko Mutsuyoshi, Hiroki Ishii, Momoko Matsuyama, Taisuke Kitano, Mitsutoshi Shindo, Akinori Aomatsu, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara, Yoshiyuki Morishita Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, JapanCorrespondence: Keiji HiraiDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma-Cho, Omiya-Ku, Saitama City, Saitama 330-8503, JapanTel +81-48-647-2111Fax +81-48-647-6831Email keijihirai@kfy.biglobe.ne.jpIntroduction and Objectives: We investigated the efficacy and safety of sodium-glucose cotransporter-2 (SGLT-2) inhibitors as an add-on therapy in patients with advanced-stage diabetic kidney disease taking renin-angiotensin system (RAS) blockers.Materials and Methods: Changes in glycated hemoglobin (HbA1c), urine protein-to-creatinine ratio (UACR), body weight, systolic blood pressure, and annual change in estimated glomerular filtration rate (eGFR) were retrospectively analyzed in 20 patients after 12 months of SGLT-2 inhibitor administration (mean eGFR: 22.8 ± 9.7 mL/min/1.73 m2). All patients had advanced-stage diabetic kidney disease and were taking RAS blockers. Twenty patients matched with similar propensity scores who were not taking SGLT-2 inhibitors served as the control group.Results: The annual change in eGFR improved significantly from − 8.6 ± 12.5 mL/min/1.73 m2/year to − 2.6 ± 5.0 mL/min/1.73 m2/year after 12 months by SGLT-2 inhibitor administration (p < 0.05), but did not change in the control group. Other clinical parameters, such as HbA1c, UACR, body weight, blood pressure, serum lipids, and electrolytes did not change in either group. No adverse effects were observed by taking SGLT-2 inhibitors.Conclusion: Using SGLT-2 inhibitors as an add-on therapy may have beneficial effects on renal function in patients with advanced-stage diabetic kidney disease taking RAS blockers without any adverse effects.Keywords: advanced-stage diabetic kidney disease, renin-angiotensin system blocker, sodium-glucose cotransporter-2 inhibitorHirai KMorino JMinato SKaneko SYanai KMutsuyoshi YIshii HMatsuyama MKitano TShindo MAomatsu AMiyazawa HIto KUeda YOokawara SMorishita YDove Medical Pressarticleadvanced-stage diabetic kidney diseaserenin-angiotensin system blockersodium-glucose cotransporter-2 inhibitorSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 215-225 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
advanced-stage diabetic kidney disease renin-angiotensin system blocker sodium-glucose cotransporter-2 inhibitor Specialties of internal medicine RC581-951 |
| spellingShingle |
advanced-stage diabetic kidney disease renin-angiotensin system blocker sodium-glucose cotransporter-2 inhibitor Specialties of internal medicine RC581-951 Hirai K Morino J Minato S Kaneko S Yanai K Mutsuyoshi Y Ishii H Matsuyama M Kitano T Shindo M Aomatsu A Miyazawa H Ito K Ueda Y Ookawara S Morishita Y The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers |
| description |
Keiji Hirai, Junki Morino, Saori Minato, Shohei Kaneko, Katsunori Yanai, Yuko Mutsuyoshi, Hiroki Ishii, Momoko Matsuyama, Taisuke Kitano, Mitsutoshi Shindo, Akinori Aomatsu, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara, Yoshiyuki Morishita Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, JapanCorrespondence: Keiji HiraiDivision of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma-Cho, Omiya-Ku, Saitama City, Saitama 330-8503, JapanTel +81-48-647-2111Fax +81-48-647-6831Email keijihirai@kfy.biglobe.ne.jpIntroduction and Objectives: We investigated the efficacy and safety of sodium-glucose cotransporter-2 (SGLT-2) inhibitors as an add-on therapy in patients with advanced-stage diabetic kidney disease taking renin-angiotensin system (RAS) blockers.Materials and Methods: Changes in glycated hemoglobin (HbA1c), urine protein-to-creatinine ratio (UACR), body weight, systolic blood pressure, and annual change in estimated glomerular filtration rate (eGFR) were retrospectively analyzed in 20 patients after 12 months of SGLT-2 inhibitor administration (mean eGFR: 22.8 ± 9.7 mL/min/1.73 m2). All patients had advanced-stage diabetic kidney disease and were taking RAS blockers. Twenty patients matched with similar propensity scores who were not taking SGLT-2 inhibitors served as the control group.Results: The annual change in eGFR improved significantly from − 8.6 ± 12.5 mL/min/1.73 m2/year to − 2.6 ± 5.0 mL/min/1.73 m2/year after 12 months by SGLT-2 inhibitor administration (p < 0.05), but did not change in the control group. Other clinical parameters, such as HbA1c, UACR, body weight, blood pressure, serum lipids, and electrolytes did not change in either group. No adverse effects were observed by taking SGLT-2 inhibitors.Conclusion: Using SGLT-2 inhibitors as an add-on therapy may have beneficial effects on renal function in patients with advanced-stage diabetic kidney disease taking RAS blockers without any adverse effects.Keywords: advanced-stage diabetic kidney disease, renin-angiotensin system blocker, sodium-glucose cotransporter-2 inhibitor |
| format |
article |
| author |
Hirai K Morino J Minato S Kaneko S Yanai K Mutsuyoshi Y Ishii H Matsuyama M Kitano T Shindo M Aomatsu A Miyazawa H Ito K Ueda Y Ookawara S Morishita Y |
| author_facet |
Hirai K Morino J Minato S Kaneko S Yanai K Mutsuyoshi Y Ishii H Matsuyama M Kitano T Shindo M Aomatsu A Miyazawa H Ito K Ueda Y Ookawara S Morishita Y |
| author_sort |
Hirai K |
| title |
The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers |
| title_short |
The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers |
| title_full |
The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers |
| title_fullStr |
The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers |
| title_full_unstemmed |
The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers |
| title_sort |
efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with advanced-stage diabetic kidney disease taking renin-angiotensin system blockers |
| publisher |
Dove Medical Press |
| publishDate |
2020 |
| url |
https://doaj.org/article/2d0096a0788643f19bc4f1fe2dcd0bec |
| work_keys_str_mv |
AT hiraik theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT morinoj theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT minatos theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT kanekos theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT yanaik theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT mutsuyoshiy theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT ishiih theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT matsuyamam theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT kitanot theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT shindom theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT aomatsua theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT miyazawah theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT itok theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT ueday theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT ookawaras theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT morishitay theefficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT hiraik efficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT morinoj efficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT minatos efficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT kanekos efficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT yanaik efficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT mutsuyoshiy efficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT ishiih efficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT matsuyamam efficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT kitanot efficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT shindom efficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT aomatsua efficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT miyazawah efficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT itok efficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT ueday efficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT ookawaras efficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers AT morishitay efficacyandsafetyofsodiumglucosecotransporter2inhibitorsinpatientswithadvancedstagediabetickidneydiseasetakingreninangiotensinsystemblockers |
| _version_ |
1718400341519630336 |